Analyst Reco. NovoCure Limited

Equities

NVCR

JE00BYSS4X48

Market Closed - Nasdaq Other stock markets 16:00:00 2024-04-26 EDT			5-day change	1st Jan Change
12.64 ^USD	+3.31%		+4.51%	-15.37%

04-24	NovoCure Limited Announces Results of the Metis Phase 3 Clinical Trial in Brain Metastases from Non-Small Cell Lung Cancer	CI
04-10	Piper Sandler Raises NovoCure's Price Target to $28 From $25, Maintains Overweight Rating	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Piper Sandler Raises NovoCure's Price Target to $28 From $25, Maintains Overweight Rating	04-10	MT
Wells Fargo Cuts Price Target on NovoCure to $42 From $49, Keeps Overweight Rating	04-03	MT
Evercore ISI Adjusts Price Target on NovoCure to $15 From $14, Keeps In Line Rating	02-23	MT
Wedbush Adjusts NovoCure Price Target to $21 From $23, Maintains Neutral Rating	23-10-26	MT
Wells Fargo Adjusts NovoCure's Price Target to $49 From $102, Keeps Overweight Rating	23-08-29	MT
Wedbush Cuts NovoCure's Price Target to $23 From $46 After Drug Failure in Clinical Study, Maintains Neutral Rating	23-08-28	MT
HC Wainwright Downgrades NovoCure to Neutral From Buy, Cuts Price Target to $25 From $85	23-08-28	MT
Piper Sandler Lowers Price Target on NovoCure to $35 From $45, Maintains Overweight Rating	23-08-28	MT
Wedbush Cuts NovoCure's Price Target to $23 From $46, Maintains Neutral Rating	23-08-28	MT
Piper Sandler Upgrades NovoCure to Overweight From Neutral, Price Target is $45	23-08-08	MT
SVB Securities Initiates NovoCure at Outperform With $51 Price Target	23-08-04	MT
Evercore ISI Upgrades NovoCure to In Line From Underperform, Price Target is $33	23-07-31	MT
Wedbush Upgrades NovoCure to Neutral From Underperform After Additional Details From LUNAR Study, Notes Limited Near-Term Catalysts; Lowers PT to $46 From $53	23-06-07	MT
Piper Sandler Adjusts Price Target on NovoCure to $62 From $67, Maintains Neutral Rating	23-06-07	MT
Wedbush Upgrades NovoCure to Neutral From Underperform After Additional Details From LUNAR Study, Notes Limited Near-Term Catalysts; Lowers PT to $46 From $53	23-06-07	MT
Wells Fargo Upgrades NovoCure to Overweight From Equalweight, Adjusts Price Target to $104 From $70	23-05-16	MT
Wedbush Cuts NovoCure's Price Target to $53 From $65 After Lower-Than-Expected Q1 Results, Keeps Underperform Rating	23-05-05	MT
JPMorgan Downgrades NovoCure to Underweight From Neutral, Adjusts Price Target to $50 From $99	23-03-17	MT
Piper Sandler Adjusts NovoCure's Price Target to $80 From $70, Maintains Neutral Rating	23-01-17	MT
JPMorgan Adjusts NovoCure's Price Target to $99 From $86, Keeps Neutral Rating	23-01-06	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. NovoCure Limited

Equities

NVCR

JE00BYSS4X48

Analyst Reco.

Filters